Cardax

Cardax EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cardax (CDXI) as of Oct 19, 2026 is -3.03 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -4.04 M USD — a change of -25.00% (higher).

EBITDA

-3.03 MUSD

YoY

-25.00%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cardax is 2020 -3.03 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cardax was 2019 -4.04 M USD. It decreases by -25.00% higher compared to the previous year.

The Cardax EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2015
-4.38 M USD
Jan 1, 2016
-1.80 M USD
Jan 1, 2017
-1.97 M USD
Jan 1, 2018
-3.99 M USD
Jan 1, 2019
-4.04 M USD
Jan 1, 2020
-3.03 M USD
The Cardax EBITDA history
YEAREBITDAYoY
-3.03 MUSD-25.00%
-4.04 MUSD+1.14%
-3.99 MUSD+102.34%
-1.97 MUSD+9.54%
-1.80 MUSD-58.85%
-4.38 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardax Stock analysis

What does Cardax do? Cardax Inc, a development stage biopharmaceutical company based in Honolulu, Hawaii, focuses on developing pharmaceuticals for chronic diseases driven by inflammation. The company has 10 full-time employees and went public via an IPO on January 30, 2012. Cardax is currently developing two pre-clinical pharmaceutical candidates: CDX-101 and CDX-301. CDX-101 is a proprietary astaxanthin prodrug designed to deliver astaxanthin to the bloodstream following oral administration. Astaxanthin is a naturally occurring molecule known for its anti-inflammatory properties, supporting cardiovascular health, metabolic health, liver health, joint health, and longevity. CDX-301 is a pharmaceutical candidate for macular degeneration, utilizing zeaxanthin, which accumulates in the human eye through a retinal receptor to protect against blue light, oxidative damage, and inflammation associated with macular degeneration. The company's headquarters are located in Honolulu, and it operates within the Health Care sector, specifically in the Pharmaceuticals industry. Cardax Inc's website is https://cardaxpharma.com/. The company is seeking to monetize its pre-clinical candidates, CDX-101 and CDX-301, as it advances its development pipeline. No additional details about the company's financials, specific acquisition history, or other product names are provided in the available information. Cardax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cardax stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cardax is -3.03 M USD in 2020.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cardax changed from -4.04 M USD to -3.03 M USD, representing a -25.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Cardax since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Cardax historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cardax

All Key Metrics — Cardax